Molecular Biology of Medulloblastoma: Will It Ever Make a Difference to Clinical Management?
- 1 December 2005
- journal article
- childhood brain-tumors
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 75 (3) , 273-278
Abstract
Summary Over the last 10 years approximately 750 children with medulloblastoma have been treated on consortia based clinical trials at an estimated cost of over $150 million. Despite this enormous effort, no meaningful molecular data has been generated that will inform the next generation of clinical studies. It is imperative that the neuro-oncology community give greater priority to studies of medulloblastoma molecular biology: unless we do this our patients will face a bleak future in which there is no accurate disease-risk stratification tool and no effective new treatments. We review some of the reasons we have failed to translate knowledge of medulloblastoma disease biology to the clinic and look forward to the next generation of clinical and molecular studies that are seeking to correct this.Keywords
This publication has 38 references indexed in Scilit:
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for MedulloblastomaJournal of Clinical Oncology, 2004
- Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profilingCarcinogenesis, 2003
- PDGFRB is overexpressed in metastatic medulloblastomaNature Genetics, 2003
- Prediction of central nervous system embryonal tumour outcome based on gene expressionNature, 2002
- C-MYC expression in medulloblastoma and its prognostic valueInternational Journal of Cancer, 2000
- APC Mutations in Sporadic MedulloblastomasThe American Journal of Pathology, 2000
- The Hallmarks of CancerCell, 2000
- Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumoursOncogene, 1997